Recent developments in chemotherapy of advanced gastric cancer

被引:3
作者
Götze, T
Schütte, K
Röcken, C
Malfertheiner, P
Ebert, MPA
机构
[1] Univ Magdeburg, Dept Gastroenterol Hepatol & Infect Dis, DE-39120 Magdeburg, Germany
[2] Univ Magdeburg, Inst Pathol, DE-39120 Magdeburg, Germany
关键词
gastric cancer; palliative treatment; taxane; irinotecan; oxaliplatin; capecitabine;
D O I
10.1159/000083599
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Approximately 1 million individuals develop gastric cancer every year and the mortality of gastric cancer is only second to lung cancer. The poor prognosis is caused by late diagnosis of most cancers in advanced stages and the limited therapeutic options in these stages. Apart from the elucidation of underlying molecular and genetic changes in the development and progression of gastric cancers, the development of new treatment strategies is critical for the improvement of the treatment and prognosis of these patients. In this review we have summarized and critically assessed recent studies dealing with the chemotherapy of advanced gastric cancer. While the efficacy of most treatment regimens is only limited, new developments may indicate that treatment with chemotherapy may confer some benefit in the future. Copyright (C) 2004 S. Karger AG, Basel.
引用
收藏
页码:360 / 365
页数:6
相关论文
共 36 条
  • [1] AJANI J, 2003, P AN M AM SOC CLIN, V22, pA258
  • [2] CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma - Results of a Phase II study
    Ajani, JA
    Baker, J
    Pisters, PWT
    Ho, L
    Mansfield, PF
    Feig, BW
    Charnsangavej, C
    [J]. CANCER, 2002, 94 (03) : 641 - 646
  • [3] Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer
    Al-Batran, SE
    Atmaca, A
    Hegewisch-Becker, S
    Jaeger, D
    Hahnfeld, S
    Rummel, MJ
    Seipelt, G
    Rost, A
    Knuth, JOA
    Jaeger, E
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (04) : 658 - 663
  • [4] Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma
    Assersohn, L
    Brown, G
    Cunningham, D
    Ward, C
    Oates, J
    Waters, JS
    Hill, ME
    Norman, AR
    [J]. ANNALS OF ONCOLOGY, 2004, 15 (01) : 64 - 69
  • [5] Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer
    Boku, N
    Ohtsu, A
    Shimada, Y
    Shirao, K
    Seki, S
    Saito, H
    Sakata, Y
    Hyodo, I
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) : 319 - 323
  • [6] BOUCHE O, 2003, P AN M AM SOC CLIN, V22, pA1033
  • [7] Irinotecan in the treatment of gastric cancer
    Bugat, R
    [J]. ANNALS OF ONCOLOGY, 2003, 14 : 37 - 40
  • [8] CHUN H, 1999, P AN M AM SOC CLIN, V18, pA280
  • [9] Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy
    Chun, JH
    Kim, HK
    Lee, JS
    Choi, JY
    Lee, HG
    Yoon, SM
    Choi, IJ
    Ryu, KW
    Kim, YW
    Bae, JM
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2004, 34 (01) : 8 - 13
  • [10] COCCONI G, 2001, P AN M AM SOC CLIN, V20, pA501